gsk news - Search News

GSK, Shingles

Hosted on MSN · 2d

GSK's RSV vaccine meets main goal when co-administered with shingles shot

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.

pulmonologyadvisor · 3h

GSK Reports Findings on Coadministered RSV and Shingles Vaccines

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

Business Insider · 2d

GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines

GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the

Reuters on MSN · 2d

GSK's RSV, Shingles vaccines show on-par immune response in joint trial

(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.

Seeking Alpha on MSN · 1d

GSK posts late-stage trial win for co-administered RSV and shingles vaccines

GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.

1h

GSK falls Friday, underperforms market

GSK PLC GSK shares slipped 2.45% to £15.36 Friday, on what proved to be an all-around grim trading session for the stock ...

23h

Boehringer, GSK, Pfizer Still Face Zantac Cases Despite Mistrial

An Illinois mistrial involving the recalled medication Zantac is the latest court decision involving the recalled drug, but ...

6d

GSK, iTeos Lung Cancer Data Set to Reignite Hope for Drug Class

Early data from GSK Plc and iTeos Therapeutics’ mid-stage trial of a lung cancer medicine looks set to renew cautious ...

Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target

A targeted immunotherapy being developed by iTeos Therapeutics and GSK, it was reported at #ESMO, delivered promising ...

FierceBiotech6d

UPDATED: iTeos-GSK's TIGIT combo shows 30% more tumor shrinkage than Jemperli, but safety signals scare investors

After announcing a phase 3 launch based on positive midstage results, iTeos and GSK are finally sharing the highlights from ...

GSK, iTeos Score Phase II Win for Jemperli-TIGIT Combo in NSCLC

High response rates reported by GSK and iTeos at the 2024 European Society for Medical Oncology Congress offer a ray of light ...

3d

GSK falls Tuesday, underperforms market

Shares of GSK PLC GSK dropped 1.38% to £16.10 Tuesday, on what proved to be an all-around favorable trading session for the ...

2d

GSK settles two California lawsuits related to heartburn drug Zantac

British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results